At the Tufts Center for Vision Research and the New England Eye Center, our clinicians and scientists are unlocking the mysteries of the most common and difficult to treat forms of eye disease. Whether developing novel treatments or pioneering new technologies, Tufts experts are leading discovery for better medicine—and creating new hope for millions of patients at risk of blindness.
Tufts Ophthalmology Highlights
- Tufts researchers are closing in on two breakthrough, nonsurgical treatments for age-related macular degeneration (AMD) and diabetic retinopathy, using new techniques in gene therapy aimed at the root of the disease.
- Collaborative research between Tufts researchers and pharmaceutical companies has resulted in two of the most commonly prescribed eye treatments in use today—Eylea and Lucentis.
- With MIT’s support, we pioneered the gold standard in vision diagnostic technology—optical coherence tomography (OCT)—now used worldwide to monitor and treat diseases such as AMD and glaucoma.
- The Tufts ophthalmology training program is world-renowned and attracts 600 applications annually—among the most competitive in the nation.
- Our faculty are on the list of the top 15 most-cited authors internationally—an indicator of our leadership and influence.
- The leading vision foundations are behind us—our research attracts funding and awards from the National Eye Institute, Research to Prevent Blindness, the Foundation Fighting Blindness, and Prevent Blindness America.
Read more about our Principal Faculty in Vision Research.